Development and Validation of Highly Sensitive LC–ESI-MS/MS Method for Bortezomib and Its Applications for Plasma Levels and Drug Content of Branded and Generic Formulations in India-Reference-Cited by-同舟云学术

Development and Validation of Highly Sensitive LC–ESI-MS/MS Method for Bortezomib and Its Applications for Plasma Levels and Drug Content of Branded and Generic Formulations in India

Published:2022-01-21 Issue:2 Volume:85 Page:127-135
ISSN:0009-5893
Container-title:Chromatographia
language:en
Short-container-title:Chromatographia

Author:

Goel Lavisha,Das Ujjalkumar Subhash,Gupta Pooja^ORCID,Velpandian Thirumurthy,Kumar Lalit,Singh Archana,Luthra Kalpana,Gupta Yogendra Kumar

Funder

Science and Engineering Research Board

Publisher

Springer Science and Business Media LLC

Subject

Organic Chemistry,Clinical Biochemistry,Biochemistry,Analytical Chemistry

Link

https://link.springer.com/content/pdf/10.1007/s10337-021-04121-z.pdf

Reference15 articles.

1. Rosinol L, Oriol A, Rios R, Sureda A, Blanchard MJ, Hernandez MT, Martinez-Martinez R, Moraleda JM, Jarque I, Bargay J, Gironella M, Arriba FD, Palomera L, Gonzalez-Montes Y, Marti JM, Krsnik I, Arguinano JM, Gonzalez ME, Gonzalez AP, Casado LF, Lopez-Anglada L, Paiva B, Mateos MV, Miguel JFS, Lahuerta JJ, Blade J (2019) Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. https://doi.org/10.1182/blood.2019000241

2. Attal M, Lauwers-cances V, Hulin C, Pessac B, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P (2017) Lenalidomide, bortezomib, and dexamethasone with transplantation in myeloma. N Engl J Med. https://doi.org/10.1056/NEJMoa1611750

3. Liu ZA, Xia HL, Li CJ, Xia L (2019) Incidence and risk of peripheral neuropathy caused by intravenous and subcutaneous injection of bortezomib. Zhongguo Shi Yan Xue Ye Xue Za Zhi. https://doi.org/10.19746/j.cnki.issn.1009-2137.2019.05.046 (Chinese)

4. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. https://doi.org/10.1200/JCO.2004.02.106

5. Andriamanana I, Gana I, Duretz B, Hulin A (2013) Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS. J Chromatogr B. https://doi.org/10.1016/j.jchromb.2013.01.037

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Determination of bortezomib and dasatinib anticancer drugs in real samples using an electrochemical sensor modified with new CuFe2O4/SmVO4/ionic liquid nanocomposite;Carbon Letters;2023-11-06